Volume 11, Issue 1 (3-2023)                   JoMMID 2023, 11(1): 60-61 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Abdul Samad S, Kallarakkal H, Basheer N. Intraventricular Administration of Cefepime for the Treatment of Meningitis due to Pseudomonas aeruginosa. JoMMID 2023; 11 (1) :60-61
URL: http://jommid.pasteur.ac.ir/article-1-515-en.html
Intraventricular Administration of Cefepime for the Treatment of Meningitis due to Pseudomonas aeruginosa
Sameer Abdul Samad , Hafeedha Kallarakkal , Noufal Basheer
Department of Infectious Diseases, Aster Malabar Institute of Medical Sciences, Calicut, India
Abstract:   (798 Views)
Beta-lactam antibiotics are traditionally not considered for intrathecal therapy, despite their poor penetration into the cerebrospinal fluid (CSF) during intravenous therapy, because target concentrations of the beta-lactam antibiotic in the central nervous system can usually be achieved with a higher intravenous dose [1]. However, in cases where inadequate clinical response is seen even with maximal doses of intravenous antibiotics, and when access for intraventricular administration of antibiotics is available, this route can be utilized for patient management, as we report now. Cefepime at high doses has been reported to cause seizures and encephalopathy [2]. However, therapeutic intraventricular administration of cefepime for the management of nosocomial meningitis, leading to successful microbiological clearance has not been reported previously in the literature.
Keywords: Intraventricular, Cefepime, Pseudomonas
Full-Text [PDF 418 kb]   (329 Downloads)    
Type of Study: Letter to the Editor | Subject: Anti-microbial agents, resistance and treatment protocols
Received: 2022/12/14 | Accepted: 2023/02/28 | Published: 2023/05/20
References
1. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010; 23 (4): 858-83. [DOI:10.1128/CMR.00007-10]
2. Reza M, Bagert B, Reese G, Reeves MA. Cefepime-induced Neurotoxicity in the Critically Ill: A Modifiable Risk Factor (P7-12.001). Neurology. 2022; 98 (18 Supplement).
3. Pacifici GM, Marchini G. Clinical Pharmacology of Cefepime in Infants and Children. Int J Pediatr. 2017; 5 (4): 4723-40.
4. Durand-Maugard C, Lemaire-Hurtel AS, Gras-Champel V, Hary L, Maizel J, Prud'homme-Bernardy A, et al. Blood and CSF monitoring of cefepime-induced neurotoxicity: nine case reports. J Antimicrob Chemother. 2012; 67 (5): 1297-9. [DOI:10.1093/jac/dks012]
5. Payne LE, Gagnon DJ, Riker RR, Seder DB, Glisic EK, Morris JG, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017; 21 (1): 276. [DOI:10.1186/s13054-017-1856-1]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.